ImmunityBio IBRX 深 沪
已收盘 11-13 16:00:00 美东时间
6.02
-0.050
-0.82%
华盛通- 最 高6.17
- 今 开6.105
- 成交量 1333.07万股
- 最 低 5.8301
- 昨 收 6.07
- 总市值 64.04亿
- 52周最高 12.43
- 市盈率 静 --
- 换手率 1.25%
- 52周最低 1.95
- 委 比 -14.31%
- 总股本 10.64亿
- 历史最高 45.42
- 量 比 0.62
- 振 幅 5.60%
- 历史最低 0.93
- 每 手 1
- 风险率 2.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股周涨跌榜 | AMD、博通周升超18%，成英伟达领导层动荡中的潜在赢家！Cerebras周涨逾21%
AMD、博通周内双双劲升逾18%，成英伟达领导层动荡中的潜在赢家！Cerebras周涨逾21%，Q3业绩超预期；摩丁制造升逾40%，传三星电子洽谈收购公司>>
今天 10:26
ImmunityBio Reports Wider Quarterly Loss
ImmunityBio Inc. (NASDAQ:IBRX) stock is trading lower on Monday after the company’s third-quarter earnings missed expectations. The company reported an adjusted loss of 9 cents, missing the consensus loss of 8 cents. Adjusted net loss widened to $97.9 million in the quarter, up from $72.4 million a ...
11-09 23:31
ImmunityBio shares are trading lower after the company reported worse-than-expected Q3 financial results.
ImmunityBio shares are trading lower after the company reported worse-than-expected Q3 financial results.
11-09 21:56
ImmunityBio Q3 Adj. EPS $(0.09) Misses $(0.08) Estimate, Sales $48.841M Miss $59.250M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 28.57 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $48.841 million w...
11-09 21:01
ImmunityBio Reports Positive ANKTIVA Bladder Cancer Trial Results
ImmunityBio ( ($IBRX) ) has issued an announcement. On November 9, 2026, Immuni...
11-09 19:59
ImmunityBio Treats First Patient In Europe With ANKTIVA In Combination With Bacillus Calmette-Guérin
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NM...
11-04 21:09
Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original
On CNBC’s “Mad Money Lightning Round,” Jim Cramer said ImmunityBio, Inc. (NASDAQ:IBRX) is a “very good spec.” ImmunityBio, on Oct. 14, announced that the FDA expanded the approved indication for its bladder cancer immunotherapy ANKTIVA to include BCG-unresponsive non-muscle-invasive bladder cancer w...
10-27 20:31
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
Spero Therapeutics appoints Amy Rock, Ph.D., as Chief Regulatory and Quality Officer and Dae Gon Ha, Ph.D., as Senior Vice President, Corporate Development. Rock brings over 25 years of experience in regulatory affairs and immunotherapy development, while Ha has expertise in biopharma markets and business development. Additionally, Chief Operating Officer Timothy Keutzer will retire after 11 years, during which he played a key role in advancing U...
10-26 12:00
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
10-21 01:35
